Table 3.
Hazard Ratio (95% CI) Continuous | p-value | Hazard Ratio (95% CI) Dichotomous* | p-value | Hazard Ratio (95% CI) Continuous | p-value | Hazard Ratio (95% CI) Dichotomous* | p-value | |
---|---|---|---|---|---|---|---|---|
VE/VCO2 slope | ||||||||
All Cardiac Events | Cardiac Mortality | |||||||
Overall (263 events; 199 deaths) | 1.06 (1.05–1.07) | <0.001 | 4.1 (3.2–5.3) | <0.001 | 1.05 (1.04–1.06) | <0.001 | 3.5 (2.7–4.7) | <0.001 |
6 months post CPX (187 events; 164 deaths) | 1.05 (1.04–1.06) | <0.001 | 3.3 (2.5–4.4) | <0.001 | 1.05 (1.04–1.06) | <0.001 | 3.2 (2.3–4.4) | <0.001 |
12 months post CPX (136 events; 124 deaths) | 1.06 (1.04–1.07) | <0.001 | 3.4 (2.4–4.8) | <0.001 | 1.05 (1.04–1.07) | <0.001 | 3.3 (2.3–4.7) | <0.001 |
18 months post CPX (95 events; 89 deaths) | 1.06 (1.04–1.07) | <0.001 | 3.4 (2.3–5.1) | <0.001 | 1.06 (1.04–1.07) | <0.001 | 3.5 (2.3–5.3) | <0.001 |
24 months post CPX (67 events; 64 deaths) | 1.05 (1.04–1.07) | <0.001 | 3.4 (2.1–5.5) | <0.001 | 1.05 (1.04–1.07) | <0.001 | 3.5 (2.2–5.8) | <0.001 |
30 months post CPX (47 events; 45 deaths) | 1.05 (1.02–1.07) | <0.001 | 2.6 (1.5–4.7) | 0.001 | 1.05 (1.02–1.07) | <0.001 | 2.9 (1.6–5.2) | <0.001 |
36 months post CPX (32 events; 31 deaths) | 1.05 (1.02–1.08) | 0.001 | 2.4 (1.2–4.8) | 0.01 | 1.05 (1.02–1.08) | 0.001 | 2.5 (1.2–5.1) | 0.01 |
42 months post CPX (19 events; 19 deaths) | 1.05 (1.00–1.09) | 0.05 | 2.2 (0.90–5.6) | 0.08 | 1.05 (1.00–1.09) | 0.05 | 2.2 (0.90–5.6) | 0.08 |
Peak VO2 | ||||||||
All Cardiac Events | Cardiac Mortality | |||||||
Overall (263 events; 199 deaths) | 0.88 (0.86–0.91) | <0.001 | 3.2 (2.4–4.2) | <0.001 | 0.91 (0.88–0.93) | <0.001 | 2.3 (1.6–3.2) | <0.001 |
6 months post CPX (187 events; 164 deaths) | 0.90 (0.88–0.93) | <0.001 | 2.6 (1.8–3.7) | <0.001 | 0.91 (0.89–0.94) | <0.001 | 2.2 (1.5–3.3) | <0.001 |
12 months post CPX (136 events; 124 deaths) | 0.91 (0.88–0.94) | <0.001 | 2.0 (1.3–3.2) | 0.002 | 0.92 (0.88–0.95) | <0.001 | 1.8 (1.1–3.0) | 0.02 |
18 months post CPX (95 events; 89 deaths) | 0.92 (0.89–0.96) | <0.001 | 1.7 (0.95–3.1) | 0.07 | 0.93 (0.89–0.96) | <0.001 | 1.7 (0.93–3.2) | 0.08 |
24 months post CPX (67 events; 64 deaths) | 0.96 (0.91–1.00) | 0.03 | 1.1 (0.45–2.5) | 0.82 | 0.95 (0.91–1.00) | 0.03 | 1.2 (0.5–2.7) | 0.73 |
30 months post CPX (47 events; 45 deaths) | 0.96 (0.91–1.01) | 0.10 | 1.3 (0.53–3.4) | 0.53 | 0.96 (0.91–1.01) | 0.10 | 1.4 (0.56–3.6) | 0.47 |
36 months post CPX (32 events; 31 deaths) | 0.97 (0.92–1.03) | 0.34 | 1.6 (0.57–4.7) | 0.36 | 0.98 (0.92–1.04) | 0.44 | 1.7 (0.59–4.9) | 0.32 |
42 months post CPX (19 events; 19 deaths) | 0.95 (0.88–1.03) | 0.26 | 2.2 (0.63–7.5) | 0.22 | 0.95 (0.88–1.03) | 0.26 | 2.2 (0.63–7.5) | 0.22 |
Thresholds: VE/VCO2 slope </≥36, Peak VO2 </≥10 ml• kg−1•min−1